Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00072904 · ClinicalTrials.gov registry record · Phase 3
Diabetes Therapy to Improve BMI and Lung Function in CF
A Phase 3 study of Diabetes Mellitus and Cystic Fibrosis, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 3
- Development phase
- 108
- Enrollment target
- 7
- Study locations
NCT00072904: Completed Phase 3 study of Diabetes Mellitus and Cystic Fibrosis, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
NCT00072904 is a Phase 3 study of Diabetes Mellitus and Cystic Fibrosis that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 108 participants, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (94% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00072904, a Phase 3 study of Diabetes Mellitus and Cystic Fibrosis, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 108 participants
- Enrollment target
- 7
- Study locations
Study Summary
To recruit 150 adult patients with cystic fibrosis related diabetes (CFRD) without fasting hyperglycemia for a multi-center, twelve month, placebo-controlled intervention trial testing the ability of insulin or repaglinide to improve body mass index (BMI) and stabilize pulmonary function in cystic fibrosis (CF).
Conditions Studied
Interventions
- DRUG Repaglinide
- DRUG Insulin Asparte
Study Locations (7)
California
- Stanford University - Palo Alto
Massachusetts
- Baystate Medical Center - Springfield
Minnesota
- University of Minnesota Medical Center - Minneapolis
Pennsylvania
- Children's Hospital of Pittsburgh - Pittsburgh
Tennessee
- Vanderbilt University Medical Center - Nashville
Utah
- University of Utah - Salt Lake City
Ontario
- St. Michael's Hospital - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2001-06 |
| Est. Completion | 2007-12 |
| Phase | Phase 3 |
What the finished NCT00072904 record still lists
NCT00072904 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Repaglinide is the first listed.
NCT00072904 lists 7 locations in 7 states (California, Massachusetts, Minnesota).
Frequently Asked Questions
What is clinical trial NCT00072904 about?
NCT00072904 is a clinical study titled "Diabetes Therapy to Improve BMI and Lung Function in CF". To recruit 150 adult patients with cystic fibrosis related diabetes (CFRD) without fasting hyperglycemia for a multi-center, twelve month, placebo-controlled intervention trial testing the ability of insulin or repaglinide to improve body mass index (BMI) and stabilize pulmonary function in cystic f...
What is the current status of trial NCT00072904?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 108 participants. The study started on 2001-06. Estimated completion is 2007-12.
What conditions does trial NCT00072904 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Cystic Fibrosis.
What interventions are being tested in trial NCT00072904?
The interventions under investigation include: Repaglinide (DRUG), Insulin Asparte (DRUG).
Who is sponsoring clinical trial NCT00072904?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00072904 being conducted?
This trial has 7 study locations across California, Massachusetts, Minnesota, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00072904's enrollment target sits among peer trials
108 115th of 208 higher than 93 of 208 other Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer
RECRUITING · Phase 3
-
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
RECRUITING · Phase 3
-
Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus
COMPLETED · Phase 3
-
Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents
COMPLETED · Phase 3
-
Treatment of Peripheral Neuropathy in Patients With Diabetes
COMPLETED · Phase 3
-
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia